Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy

Menopause

Volumn 5, Issue 4, 1998, Pages 217-222

  Raudaskoski, Tytti ^a   Knip, Mikael ^a   Laatikainen, Timo ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Insulin like growth factor binding protein 1; Insulin like growth factor binding protein 3; Insulin like growth factor I; Levonorgestrel intrauterine system; Transdermal estrogen

Indexed keywords

ESTRADIOL; GESTAGEN; LEVONORGESTREL; NETA; NORETHISTERONE ACETATE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLIMACTERIUM; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INTRAUTERINE DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031744698     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-199805040-00006     Document Type: Article

References (29)

1. Baxter RC, Martin JL. Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res 1989;1:49-68.
2. Figueroa JA, Yee D. The insulin-like growth factor binding proteins (IGFPs) in human breast cancer. Breast Cancer Res Treat 1992;22:81-90.
3. Baxter RC, Martin JL. Structure of the M 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labelling. Proc Natl Acad Sci USA 1989;86:6898-902.
4. Suikkari A-M, Koivisto VA, Rutanen E-M, Yki-Järvinen H, Karonen S-L, Seppälä M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266-72.
5. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987;64:51-8.
6. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA,Bain RP. Impaired growth hormone secretion in the adult population. J Clin Invest 1981;67:1361-9.
7. Mohan S. Insulin-like growth factor (IGF)-binding proteins in serum - do they have additional roles besides modulating the endocrine IGF actions? [editorial]. J Clin Endocrinol Metab 1996;81:3817-20.
8. Blum WF, Ranke MB. Plasma IGFBP-3 levels as clinical indicators. In: Spencer M, ed. Modern concepts of insulin-like growth factors. Amsterdam: Elsevier, 1991:381-3.
9. Donahue LR, Hunter SJ, Sherblom AP, Rosen C. Age-related changes in serum insulin-like growth factor-binding proteins in women. J Biol Chem 1990;265:19091-9.
10. Rutanen E-M, Kärkkäinen T, Stenman U-H, Yki-Järvinen H. Aging is associated with decreased suppression of insulin-like growth factor binding protein-1 by insulin. J Clin Endocrinol Metab 1993;77:1152-5.
11. Wiedemann E, Schwartz E, Frantz AG. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man. J Clin Endocrinol Metab 1976;42:942-52.
12. Frantz AG, Rabkin MT. Effects of estrogen and sex difference on secretion of human growth hormone. J Clin Endocrinol Metab 1965;25:1470-80.
13. Dawson-Hughes B, Stern D, Goldman J, Reichlin S. Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 1986;63:424-32.
14. Weissberger AJ, Ho KKY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-81.
15. Kelly JJ, Rajkovic IA, O'Sullivan AJ, Sernia C, Ho KKY. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in postmenopausal women. Clin Endocrinol 1993;39:561-67.
16. Bellantoni MF, Harman SM, Cho DE, Blackman MR. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages. J Clin Endocrinol Metab 1991:72;172-8.
17. Campagnoli C, Biglia N, Lanza M, Lesca L, Peris C, Sismondi P. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Maturitas 1994:19;25-31.
18. Raudaskoski T, Lahti E, Kauppila A, Apaja-Sarkkinen M, Laatikainen T. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114-9.
19. Ratsula KA. Levonorgestrel releasing intracervical contraceptive device [dissertation]. Helsinki, Finland: University of Helsinki, 1989.
20. Herbert V, Lau KS, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965;25:1375-84.
21. Schwander JC, Hauri C, Froesch ER. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 1983;113:297-305.
22. Setnikar I, Rovati LC, Vens-Cappell B. Hilgenstock C. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. Arzneimittel-Forschung 1996,46:766-73.
23. Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estadiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251-8.
24. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 1996;81:2250-6.
25. Lewitt MS, Baxter RC. Regulation of growth hormone-independent insulin-like growth factor-binding protein (BB-28) in cultured human fetal liver expiants. J Clin Endocrinol Metab 1989;69:245-52.
26. Ren S-G, Braunstein GD, Cedars M, Gambone J, Judd H. Serum concentrations of two endometrial proteins are not useful for monitoring postmenopausal estrogen/progesterone therapy. Fertil Steril 1990;54:532-4.
27. Suvanto-Luukkonen E, Sundström H, Penttinen J, Kauppila A, Rutanen E-M. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 1995;22:255-62.
28. Suikkari A-M, Rutanen E-M, Seppälä M. Circulating levels of immunoreactive insulin-like growth factor-binding protein in nonpregnant women. Hum Reprod 1987;2:297.
29. Ayabe T, Tsutsumi O, Sakai H, et al. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulinlike growth factor-binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997;44:419-24.